JP2016504363A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504363A5
JP2016504363A5 JP2015550682A JP2015550682A JP2016504363A5 JP 2016504363 A5 JP2016504363 A5 JP 2016504363A5 JP 2015550682 A JP2015550682 A JP 2015550682A JP 2015550682 A JP2015550682 A JP 2015550682A JP 2016504363 A5 JP2016504363 A5 JP 2016504363A5
Authority
JP
Japan
Prior art keywords
triazolo
amine
methoxy
quinazoline
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015550682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504363A (ja
JP6306049B2 (ja
Filing date
Publication date
Priority claimed from PCT/CN2012/087865 external-priority patent/WO2014101120A1/en
Application filed filed Critical
Publication of JP2016504363A publication Critical patent/JP2016504363A/ja
Publication of JP2016504363A5 publication Critical patent/JP2016504363A5/ja
Application granted granted Critical
Publication of JP6306049B2 publication Critical patent/JP6306049B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015550682A 2012-12-28 2013-12-20 A2aアンタゴニスト特性を有するヘテロビシクロ−置換−[1,2,4]トリアゾロ[1,5−c]キナゾリン−5−アミン化合物 Expired - Fee Related JP6306049B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2012/087865 WO2014101120A1 (en) 2012-12-28 2012-12-28 Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CNPCT/CN2012/087865 2012-12-28
CNPCT/CN2013/076853 2013-06-06
PCT/CN2013/076853 WO2014101373A1 (en) 2012-12-28 2013-06-06 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder
PCT/US2013/076781 WO2014105666A1 (en) 2012-12-28 2013-12-20 Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Publications (3)

Publication Number Publication Date
JP2016504363A JP2016504363A (ja) 2016-02-12
JP2016504363A5 true JP2016504363A5 (enExample) 2017-01-12
JP6306049B2 JP6306049B2 (ja) 2018-04-04

Family

ID=51019745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015550682A Expired - Fee Related JP6306049B2 (ja) 2012-12-28 2013-12-20 A2aアンタゴニスト特性を有するヘテロビシクロ−置換−[1,2,4]トリアゾロ[1,5−c]キナゾリン−5−アミン化合物

Country Status (22)

Country Link
US (2) US9708347B2 (enExample)
EP (1) EP2945632B1 (enExample)
JP (1) JP6306049B2 (enExample)
KR (1) KR102165113B1 (enExample)
AU (1) AU2013370977B2 (enExample)
BR (1) BR112015015468B8 (enExample)
CA (1) CA2896056C (enExample)
CY (1) CY1120258T1 (enExample)
DK (1) DK2945632T3 (enExample)
ES (1) ES2667477T3 (enExample)
HR (1) HRP20180678T1 (enExample)
HU (1) HUE037950T2 (enExample)
LT (1) LT2945632T (enExample)
ME (1) ME03034B (enExample)
MX (1) MX370017B (enExample)
NO (1) NO2945632T3 (enExample)
PL (1) PL2945632T3 (enExample)
PT (1) PT2945632T (enExample)
RS (1) RS57162B1 (enExample)
RU (2) RU2018136104A (enExample)
SI (1) SI2945632T1 (enExample)
WO (3) WO2014101120A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
EP3307067B1 (en) * 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
WO2017034990A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
EP3337497B1 (en) 2015-08-21 2023-07-12 SRX Cardio, LLC Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
HK1257102A1 (zh) 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
WO2017107087A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
TW201827422A (zh) 2017-01-13 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 1,2,4-三嗪-3-胺類衍生物、其製備方法及其在醫藥上的應用
CN110382499B (zh) 2017-02-27 2023-01-03 贝达药业股份有限公司 Fgfr抑制剂及其应用
WO2018166493A1 (zh) 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
AU2018341781B2 (en) 2017-09-28 2023-03-30 Cstone Pharmaceuticals Fused ring derivative as A2A receptor inhibitor
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
JP2021512959A (ja) 2018-02-06 2021-05-20 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. ピラゾロ[1,5−a][1,3,5]トリアジン−2−アミン誘導体、その製造法、およびその医薬用途
WO2020106558A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
JP2022511778A (ja) 2018-11-30 2022-02-01 メルク・シャープ・アンド・ドーム・コーポレーション アデノシン受容体拮抗薬としての7-、8-及び10-置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
CR20210271A (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
CA3102364A1 (en) 2019-03-26 2020-10-01 Novel Pharma Inc. Long-acting fatty acid-conjugated gnrh derivatives and pharmaceutical compositions containing same
PE20231066A1 (es) 2020-02-07 2023-07-17 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1
US20240076297A1 (en) * 2020-07-24 2024-03-07 Merck Sharp & Dohme Llc Adenosine a2a and a2b receptor dual antagonists for immuno-oncology
EP4185296A4 (en) * 2020-07-24 2025-03-05 Merck Sharp & Dohme LLC DUAL ADENOSINE A2A RECEPTOR AND A2B RECEPTOR ANTAGONISTS FOR IMMUNO-ONCOLOGY
JP7858636B2 (ja) 2020-09-10 2026-05-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
CN112159411A (zh) * 2020-10-15 2021-01-01 南京工业大学 一种三氟甲基取代嘧啶并[1,3]二氮杂*化合物及其制备方法
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713383A (en) * 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
EP0181282A1 (de) * 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
WO1995035107A1 (en) * 1994-06-20 1995-12-28 Smithkline Beecham Corporation Endothelin receptor antagonists
US5571775A (en) 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
SI1283839T1 (enExample) * 2000-05-26 2005-08-31 Schering Corp
AU2001274287A1 (en) * 2000-06-20 2002-01-02 Nour Eddin Ajan Alhadid Electrical drive line
US6358964B1 (en) * 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
EP1527074A1 (en) * 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003304527B2 (en) * 2002-12-19 2010-09-09 Merck Sharp & Dohme Corp. Uses of adenosine A2a receptor antagonists
DE602004018637D1 (de) * 2003-04-09 2009-02-05 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
PE20070521A1 (es) * 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
US20090062253A1 (en) 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
EP2509983B1 (en) * 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
WO2012135084A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties

Similar Documents

Publication Publication Date Title
RU2015131148A (ru) СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ
IL275522B1 (en) Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
JP2011500774A5 (enExample)
RU2020133727A (ru) Ингибиторы shp2 и их применение
RU2443706C2 (ru) Фармацевтические соединения
CN117651700A (zh) 2-氨基苯并噻唑化合物及使用方法
AU2024332123A1 (en) Compositions comprising werner syndrome helicase inhibitors and methods of using the same
JP2022502424A5 (enExample)
JP2021518395A5 (enExample)
JP2020522570A5 (enExample)
HRP20120105T1 (hr) Aminoheterociklički spojevi
JP2015504057A5 (enExample)
WO2011035518A1 (zh) 嘧啶衍生物和类似物及其制备方法和用途
RU2012136907A (ru) Модуляторы гамма-секретазы
RU2016111675A (ru) Соединения биарилацетамида и способы их применения
JP2013500975A5 (enExample)
JP2017503867A5 (enExample)
JP2014506929A5 (enExample)
JP2012527483A5 (enExample)
JP2023520759A5 (enExample)
NZ601128A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
RU2018112230A (ru) Бициклические соединения в качестве ингибиторов atx
JP2021512954A5 (enExample)
JP2017518326A5 (enExample)
ES2637816T3 (es) Derivados de imidazo-triazina como inhibidores de PDE10